Drug Profile
Sotorasib - Amgen
Alternative Names: AMG-510; LUMAKRAS; LUMYKRASLatest Information Update: 06 Aug 2026
Price :
$50
*
At a glance
- Originator Amgen; Carmot Therapeutics
- Developer Amgen; BeOne Medicines; REVOLUTION Medicines; Verastem Oncology
- Class Antineoplastics; Piperazines; Pyridines; Pyridones; Pyrimidines; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Yes - Colorectal cancer; Non-small cell lung cancer
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Colorectal cancer; Non-small cell lung cancer
- Phase III Solid tumours
- Phase I/II Brain metastases; Pancreatic cancer
Most Recent Events
- 24 Jun 2026 Amgen completes the phase III CodeBreak 200 trial in Non Small Cell Lung Cancer(Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater, Late-stage disease) in USA, Australia, the Netherlands, the UK, Poland, Spain, Hungary, Belgium, Taiwan, Switzerland, Russia, Portugal, South Korea, Japan, Italy, Germany, France, Brazil, Canada, Denmark, Finland, Poland, Sweden, UK and Greece(NCT04303780)
- 29 May 2026 Amgen completes the phase I/II CodeBreak 100 trial in Solid tumours, Colorectal cancer, Non-small cell lung cancer (Monotherapy, Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Australia, Canada, France, Japan, Austria, Belgium, Brazil, Germany, Switzerland, Greece, Hungary, Portugal, Romania, Spain and South Korea (PO, Tablet) (NCT03600883)
- 14 Apr 2026 Amgen completes a phase III trial for Colorectal cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Australia, Germany, Greece, Italy, Spain, France, Japan, South Korea, Mexico, Taiwan and United Kingdom (PO) (NCT05198934)